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Background: Serogroup B meningococcal (MenB) isolates currently account for approximately 90% of invasive
meningococcal disease (IMD) in Greece with ST-162 clonal complex predominating. The potential of a multicomponent
meningococcal B vaccine (4CMenB) recently licensed in Europe was investigated in order to find whether the
aforementioned vaccine will cover the MenB strains circulating in Greece. A panel of 148 serogroup B invasive
meningococcal strains was characterized by multilocus sequence typing (MLST) and PorA subtyping. Vaccine
components were typed by sequencing for factor H-binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA)
and Neisseria adhesin A (NadA). Their expression was explored by Meningococcal Antigen Typing System (MATS).
Results: Global strain coverage predicted by MATS was 89.2% (95% CI 63.5%-98.6%) with 44.6%, 38.5% and 6.1% of
strains covered by one, two and three vaccine antigens respectively. NHBA was the antigen responsible for the highest
coverage (78.4%), followed by fHbp (52.7%), PorA (8.1%) and NadA (0.7%). The coverage of the major genotypes did
not differ significantly. The most prevalent MLST genotype was the ST-162 clonal complex , accounting for 44.6% of
the strains in the panel and with a predicted coverage of 86.4%, mainly due to NHBA and fHbp.
Conclusions: 4CMenB has the potential to protect against a significant proportion of Greek invasive MenB strains.
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In the global effort to eliminate bacterial meningitis and
septicemia, serogroup B Neisseria meningitidis is among
the most challenging pathogens for vaccine development
[1,2]. This is due to the fact that serogroup B capsular
polysaccharide is not immunogenic and is a potential
self-antigen [3,4]. The approach of strain-specific outer
membrane proteins has been successful in the development
of vaccines effective against homologous strains [5,6].
A novel multicomponent vaccine against invasive dis-
ease caused by meningococcal capsular group B (MenB),
4CMenB (Bexsero®), containing four major components:
factor H-binding protein (fHbp) [7], Neisserial Heparin
Binding Antigen (NHBA) [8], Neisseria Adhesin A (NadA)* Correspondence: gtzanakaki@esdy.edu.gr
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reproduction in any medium, provided the or[9], and outer membrane vesicles (OMV) derived from
the New Zealand outbreak strain NZ98/254 [10], has been
recently developed and licensed in Europe.
For vaccines based on meningococcal serogroups A,
C, W and Y capsular polysaccharide conjugates which
have been licensed in many parts of the world [11-13],
the immunogenicity has been evaluated by means of
complement–mediated killing using the serum bacteri-
cidal assay (SBA) of 4 strains belonging to each serogroup
and the coverage is estimated on the basis of the
epidemiological serogroup distribution [14-16]. This
is very difficult for the evaluation of the novel re-
combinant protein-vaccine that aimed to target ser-
ogroup B due to the fact that the protein antigens
may vary in their sequence and level of expression
across strains [17]. Phase variation, gene regulation,
and sequence diversity can in fact affect the quantity
of the target protein antigens on the bacterial surface orral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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contained in the vaccine. This diversity significantly im-
pacts the likelihood that vaccine-induced antibody re-
sponses will kill any given MenB isolate. This variability
across strains would thus require extensive testing in SBA
with human complement (hSBA) when assessing large
strain panels. Such testing is clearly problematic because
of the difficulty to standardize the hSBA across diverse
strains and sources of human complement. For this rea-
son, alternative means of measuring the probability of kill-
ing in the hSBA by antibodies induced by the surface
protein based vaccine are necessary [18].
The Meningococcal Antigen Typing System (MATS)
is an ELISA developed to evaluate whether a given strain
expresses at least one of the antigens (fHbp, NHBA and
NadA) contained in the 4CMenB vaccine and the degree
of cross-reactivity [19]. MATS also considers the PorA
variable region 2 (VR2) of the target bacteria in order to
assess the immunodominant contribution of the outer
membrane vesicle (OMV-NZ) from the New Zealand out-
break strain, which possesses PorA P1.4, to the 4CMenB
vaccine [20]. Strains that meet a minimum threshold of
reactivity to fHbp, NadA or NHBA in the MATS ELISA,
named positive bactericidal threshold (MATS-PBT), or
that possess the PorA VR2 4 are expected to be covered
by 4CMenB [19]. The baseline relationships of MATS to
hSBA represented by the MATS-PBT values were estab-
lished using pooled sera obtained from infants following
a three dose primary series of 4CMenB vaccine and a
booster dose at 12 months of age. The MATS ELISA was
then transferred to several National Meningococcal Refer-
ence Laboratories and an interlaboratory standardization
study was conducted to ensure consistent results across
European reference laboratories that allowed testing the
strain coverage in Europe and Canada [21-24].
Although the incidence of the Invasive Meningococcal
Disease (IMD) in Greece decreased from 1.94 in 1999
to 0.68 per 100,000 in 2009 upon the introduction of
conjugate MenC vaccine [25], serogroup B currently ac-
counts for approximately 90% of the IMD similarly to
other European countries. The predominant clonal com-
plex (cc), cc162, is proportionally higher as compared to
other European countries, where it represents only 2.5%
of invasive isolates, as recently published in a study con-
ducted in five European countries (Euro-5) [23]. The
aim of the present study was to investigate the potential
coverage of 4CMenB meningococcal vaccine in Greece,
with particular regards on the impact that the cc162 has
on this coverage.
Methods
Meningococcal isolates, PCR and sequencing
A total of 148 serogroup B meningococcal strains iso-
lated from cases of IMD during an 11 year period(1999–2010) collected -as part of standard patient care-
by the National Meningitis Reference Laboratory (NMRL)
at the National School of Public Health in Athens, Greece,
were studied retrospectively. This strain set is composed
of: a first subset of 52 clinical revived isolates out of the
58 (90%) collected by the NMRL during 2008–2010,
representative of endemic MenB disease burden in Greece
during that period; a remaining subset of 96 strains iso-
lated from 1999 to 2007, specifically enriched for the
cc162 (n = 66 in this subset), which was highly prevalent
in Greece but is decreasing in recent years, and for the
cc269 (n = 10 in this subset), which has recently emerged
in Greece (Figure 1). All strains were PorA subtyped using
both serosubtyping and genosubtyping, by sequencing of
the three Variable Regions VR1, VR2 and VR3 of the porA
gene [26-29]. The deduced amino acid sequences of VR1
and VR2 were assigned according to the Neisseria menin-
gitidis PorA Variable Regions Database (http://neisseria.
org/nm/typing/pora). The PorA VR3 database (http://
www.shlmprl.scot.nhs.uk/PorA_VR3.asp) was used to as-
sign VR3 subtypes.
Strains were characterized by MLST following the
guidelines included in the public MLST database (http://
pubmlst.org/neisseria/); PorA, NHBA and NadA sequence
variants (alleles and peptides) have been assigned using the
same interface as MLST. PCR and gene sequencing of
fHbp and nhba and nadA gene presence were evaluated by
previously published methods [9,30-33]. The new alleles
were deposited in GenBank under the accession numbers
KJ567159 to KJ567306 and KJ567307 to KJ567449 for
the fHbp and nhba respectively. Assembly of the se-
quences was performed using the Sequencer program
version 4.10.1 (Gene Codes Corporation) and Vector NTI
suite v11. Sequences were aligned by BioEdit http://www.
mbio.ncsu.edu/BioEdit/bioedit.html.
MATS
All isolates were analyzed by MATS ELISA to determine
the proportion of strains expected to be covered by
4CMenB. MATS ELISA was carried out at Meningococ-
cal Reference Laboratory, the Institut Pasteur (Paris,
France) which is one of the MATS reference laboratories
which participated to the inter laboratory standardization
[22,23]. MATS ELISA values were calculated as antigen-
specific relative potencies compared with MenB reference
strains expressing each vaccine antigen [19,22]. The
data were compiled and quality controlled by Novartis
Vaccines and Diagnostics.
MATS-PBT prediction of 4CMenB strain coverage
Predicted coverage using MATS-PBT was calculated as
described previously [19,22,23]. The presence of at least
one antigen with a relative potency greater than its
MATS-PBT relative potency value (0.021 for fHbp, 0.294
Figure 1 Most frequent clonal complexes among the two subsets of 96 (1999–2007) and 52 (2008–2010) Greek isolates.
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VR2 1.4 (matched to the OMV-NZ component of
4CMenB) was considered to be sufficient for a strain to be
covered by 4CMenB. Strains that did not meet these cri-
teria were considered not covered. Estimates of the 95%
confidence intervals (95% CI) for the MATS-PBTs were
derived on the basis of overall assay repeatability and re-
producibility (0.014-0.031 for fHbp, 0.169-0.511 for NHBA,
0.004-0.019 for NadA) [22]. These intervals were used to
define the 95% strain coverage interval by 4CMenB.
Results and discussion
Prevalence and diversity of the tested isolates
The tested isolates belonged to several clonal complexes
(cc). Among the 148 isolates tested by MATS, 66 (44.6%)
belonged to cc162, which is the predominant lineage
in Greece, followed by cc269 (33/148; 22.3%), cc41/44Figure 2 Most frequent clonal complexes among the 148 Greek isola
complex that were covered by at least the indicated protein are displayed.(n = 11/46; 24%) and cc32 (18/148; 12.1%) each respect-
ively, while 15 isolates (15/148; 10.1%) belonged to other
clonal complexes (cc) (cc60, cc35, cc461, cc212) or to
sequence types (STs) not currently assigned to any clonal
complex (Figure 2). The proportion of clonal complexes
in Greece was different as compared with other European
Countries, based on data recently published by Vogel and
colleagues in the Euro-5 study [23] this was particularly
true in the case of cc162, which was 44.6% in Greece but
which represented only 2.5% in other European Countries,
at least based on combined data from Germany, France,
Italy, United Kingdom and Norway and on preliminary
data from Spain and Czech Republic. The percentage of
isolates belonging to cc269 was 22.3% in Greece, higher
than in the rest of Europe, however it was quite com-
parable with data from United Kingdom. On the con-
trary, the proportion of cc41/44 isolates in Greece,tes (1999–2010). The percentages of isolates within each clonal
Table 1 Contribution of each antigen and their











No antigen 16 10.8% 10.8%
fHbp 14 9.5%
NadA 1 0.7% 44.7%
NHBA 50 33.8%
PorA 1 0.7%
fHbp + NHBA 55 37.1%
PorA + NHBA 2 1.3% 44.5%
PorA + fHbp + NHBA 9 6.1%
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Countries.
Greek isolates, including those belonging to the same
clonal complex, showed several combinations of variable
regions 1 and 2 (VR1 and VR2) in PorA. The OMV
component of the vaccine contains PorA subtype P1.7-2,
4. 11 isolates among the 148 analysed (7%) showed this
subtype. However, the immune response induced by PorA
has been shown to specifically target the VR2 4 epitope
[34]. Twelve (12) isolates (8.1%) showed VR2 4, with nine
of them belonging to cc41/44. The percentage of PorA
VR2 4 in the other European Countries was about 20%,
higher than in Greece.
The most common fHbp variant in Greece was variant
1 (66.9%) followed by variant 2 (24.3%) and variant 3
(8.8%). Among the fHbp peptides the most common was
1.15 (41/148, 27.7%) followed by peptide 2.21 (25/148,
16.9%) and 1.1, corresponding to the specific genotype
included in the 4CMenB vaccine (16/148, 10.8%). This
differed from the EURO-5 study, in which peptide 1.4
(16.2%) was the most frequent and peptides 1.15 and
2.21 were identified only in 11.4% and 2% of isolates, re-
spectively, whereas the percentage of fHbp-1.1 was quite
comparable [23]. The NHBA peptide 20 (63/148, 42.6%),
21 (33/148, 22.3%) and 2 (15/148, 10.1%) accounted for
more than 75% of the strains. This also differed from the
Euro-5 study [23] where the peptide 2 was the most fre-
quent (24.7%) and the peptide 20 was represented by 5%
of the isolates. NHBA peptide 20 was predominant in
Greece as a consequence of the prevalence of cc162.
For NadA, 18 of 148 (12%) isolates harbored nadA gene
(22.3% in the EURO-5 study), including one cc41/44
isolate, one cc212 isolate and all cc32 isolates. The
remaining isolates were devoid of nadA gene. The nadA
gene presence was slightly lower in Greece than in the rest
of Europe.
Estimated 4CMenB coverage
The analysis of Greek strains revealed that the coverage
by at least one antigen (fHbp, NHBA, NadA or PorA)
predicted by MATS was 89.2% (63.5%-98.6%) CI0.95 by
at least one antigen (Table 1). This prediction is similar
to the coverage predicted by MATS-PBT for only the 52
strains that were collected in Greece during 2008–2010,
which was 88% (60%-96%) CI0.95. The predicted cover-
age for each of the clonal complexes is shown in Table 2.
The highest predicted coverage was shown among the
strains belonging to cc32/ET-5 (100%), followed by cc269
(97% (57.6%-100%) CI0.95), cc41/44/lineage3 (94.4% (72.2%-
100%)CI0.95) and cc162 (86.4% (63.6%-100%) CI0.95).
The contribution of each antigen to coverage was vari-
able across the clonal complexes (Figure 3). NHBA showed
the highest contribution (116/148; 78.4%) followed by fHbp
(78/148; 52.7%), PorA (12/148; 8.1%) and NadA (1/148;0.7%) (Table 1). The overall contribution of NHBA was
consistently high across clonal complexes presenting cover-
age values from 11/16 (68.8%) for cc32, 49/66 (74.2%) for
cc162, 15/18 (83.3%) for cc41/44 while the highest value
was found among the cc269 isolates (32/33; 97%).
The lowest fHbp contribution was found among the
cc162 (24/66 36.3%) while higher contributions were found
among cc41/44 (12/18; 66.7%), cc269 (26/33; 78.8%) and
cc32 isolates (16/16; 100%). PorA contribution to coverage
in relation to clonal complexes revealed that PorA 1.4 was
found mainly among the cc41/44 (9/18; 50%) while low
PorA contribution was found for cc162 (2/66; 3%) and no
PorA contribution to coverage was found for cc269 and
cc32 strains. In contrast, NadA contribution to coverage
was low among cc41/44 isolates (1/18; 5.6%), while it was
not found in other clonal complexes (Figure 3).
The recent licensure of the 4CMenB vaccine in Europe
may promote recommendations for its use by national
immunization technical advisory groups. Data on strain
coverage are therefore crucial for decision making. This
study provides the first such data on the potential cover-
age of Greek MenB isolates by 4CMenB. The relevance
of this study is related to the high incidence, in Greece,
of cc162, which is rare in Europe. cc162 has been de-
scribed to be present both in disease-associated and in
carrier isolates in Greece, with a high degree of hetero-
geneity among the isolates [35,36].
When compared with killing of MenB strains in the
hSBA, MATS-PBT was shown to provide a conservative
prediction of strain coverage, especially in older age groups
(children, adolescents, and adults) [37]. Notably, the MATS
assay was not designed to assess synergistic killing effects
for strains having multiple MATS relative potencies for dif-
ferent antigens slightly below their positive bactericidal
thresholds. Using this conservative predictor, the 4CMenB
vaccine is expected to provide good strain coverage glo-
bally (89.2%) among the tested isolates (148 strains isolated
from cases of IMD during 1999–2010) and in particular
for the most prevalent ccs, which include cc162 and cc269
Table 2 MATS-PBT predicted coverage by clonal complex
Clonal Complex No of Strains Predicted coverage
ST-162 66 86.4% (63.6%-100%)CI0.95
ST-269 33 97.0% (57.6%-100%)CI0.95
ST-41/44/lineage 3 18 94.4% (72.2%-100%) CI0.95
ST-32/ET-5 16 100%
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The components of the 4CMenB vaccine contributed to
MATS-PBT predicted strain coverage singularly (for a total
of 44.6% of strains covered by one antigen) or in combin-
ation each other (44.6% covered by two or more antigens).
A key antigen contributing to the coverage of Greek iso-
lates was NHBA, predicted to cover the 78.4% of isolates.
The greater contribution of NHBA to coverage with re-
spect to the other antigens was evident for three out of the
four most frequent MLST genotypes in Greece, cc162,
cc41/44 and cc269. It was particularly relevant in the case
of cc162, for which NHBA was predicted to cover 74.2% of
isolates, whereas fHbp was predicted to cover only 36.4%
of isolates, due to a relative high proportion of fHbp vari-
ant 2 and 3. The sequence homogeneity of NHBA in iso-
lates belonging to cc162, quite always containing peptide
20, and its high contribution to predicted coverage are of
interest also due to the already described heterogeneity of
this clonal complex in Greece. Moreover, our results sug-
gest a strong association between NHBA peptide 20 and
predicted coverage. In contrast, contribution of NadA to
MATS-PBT predicted strain coverage was particularly low
in Greek isolates although the encoding gene was present
in 12% of isolates. However, recent data suggest that nadA
expression is repressed under the MATS assay experimen-
tal conditions and that this repression is attenuated by
4-hydroxyphenylacetic acid, a natural molecule released in
human saliva, thus leading to the de-repression of nadA
in vivo or by its derivatives that are produced by leuko-
cytes during inflammatory processes. These data furtherFigure 3 Contribution of each antigen to coverage in relation to clonal
be covered by each individual antigen. Isolates were defined as covered if the
positive bactericidal threshold (PBT) for fHbp, NHBA, or NadA.emphasize the conservative aspect of MATS-PBT analysis
potentially leading to an underestimation of strain cover-
age. The de-repression of nadA is expected to lead to
higher levels of NadA expression from nadA-positive
strains and to increased killing by anti-NadA antibodies
elicited by the 4CMenB vaccine [38]. Of note, PorA P1.4
was predicted to cover not only 50% of isolates belonging
to cc41/44, a clonal complex which usually associated with
PorAVR2 4, but also 3% of isolates belonging to cc162.
Recently, five European meningococcal reference labora-
tories were involved in a MATS standardization study
(Euro-5, comprising Germany, France, Italy, the United
Kingdom and Norway) [23] with an addition of Czech Re-
public and Spain providing their estimates. Beyond this first
European study, there is a need for further investigations of
strain coverage by clonal complex since the clonal complex
distribution may vary on a country-by-country basis and
the predicted strain coverage might be consequently
different. The present study provides additional evidence
on the predicted coverage for meningococci B cc162 that
in a previous European study were less representative.
The coverage predicted by MATS-PBT for the 52
strains collected in Greece during 2008–2010, a time
frame comparable with the period considered by the
Euro-5 study, was 88%. This estimation fell in the range
of coverage observed among the Euro-5 countries re-
gardless of the geographical distribution of the clonal
complexes. For instance, despite the prevalence of cc162
in the total 148 isolates, the most prevalent cc in Greece
among the 52 isolates from 2008 to 2010, was cc269
(44.2%), which was well covered (97%) by 4CMenB.
cc269 accounted for 19.5% in the Euro-5 study and was
absent in Italy. The overall frequency of coverage by at
least two antigens was similar (44.6% vs. 49.8%) in Greek
and in Euro-5 isolates respectively and the Greek isolates
fell within the range observed among the five countries
(39.6% for Italy to 53.9% for Germany) [23]. Since lack
of coverage due to point mutations is less likely forcomplex. The numbers indicate the percentage of isolates predicted to
y expressed PorA VR2 4 or had a MATS relative potency greater than the
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centage of Greek strains covered by at least two vaccine
antigens suggests that the rate of emergence of escape
variants in Greece is not expected to be different than
in other European countries. More recently, a study on
estimate of 4CMenB coverage of 157 Canadian serogroup
B isolates circulating from 2006 to 2009 has also been
published [24] In Canada, where the most frequent ccs
were cc41/44 and cc269, the overall 4CMenB MATS
predicted coverage was 66%, slighly lower than in Greek
and Euro-5 isolates, however results were similar to those
found in England and Wales.
Conclusions
At present, there is an increasing number of reports
published using MATS. Nevertheless, there has been, up
to now, no data from Greece. Our data provide a good
prediction of the potential coverage of 4CMenB in Greece
similarly to other European countries, despite differences
in the prevalence of MLST genotypes, such as cc162 and,
as a consequence, in the frequency and distribution of
fHbp, NHBA and NadA protein peptides. However, our
study argues for continuous surveillance by MATS typing
that should allow “real-time” post-implementation esti-
mates of coverage.
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